Searched for
TORRENT PHARMA SALES
India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Stocks in news: SBI, Titan, Hyundai, BSE, Torrent Pharma, Axis BankIndian markets saw volatile trading on Thursday, closing nearly unchanged despite positive signals. Several companies including SBI, Titan,...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Organon gives Sun Pharma scale and reach, but challenge lies in integration, executionSun Pharma has acquired Organon & Co for $11.75 billion. This deal provides Sun Pharma with expanded global scale and commercial reach. It ...
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakersIndia's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...
- Stocks in news: Torrent Power, GAIL, J&K Bank, Ola Electric, Vedanta, InfosysMarkets ended higher for the third consecutive session amidst volatility. Today's trade will focus on ceasefire developments and the MPC me...
- GLP-1 impact: Jefferies sees these 3 stocks as winners in the race for Ozempic, Wegovy genericsIndian drug makers are launching affordable generic Semaglutide, the active ingredient in popular weight-loss drugs. Sun Pharma, Lupin, and...
- Rs 12,000 crore magic pill race begins to shrink India's pot bellies. Which pharma stocks will win GLP-1 war?India's GLP-1 market is set for a massive boom. Following patent expiry, generic versions of semaglutide are launching at significantly low...
- Torrent Pharma seeks CCI nod to acquire majority stake in JB Chemicals for Rs 19,500 croreTorrent Pharmaceuticals is looking to acquire J B Chemicals and Pharmaceuticals. The deal is worth Rs 19,500 crore. The company has sought ...
- Torrent Pharma seeks CCI nod to acquire majority stake in JB Chemicals for Rs 19,500 crTorrent Pharmaceuticals is set to acquire a majority stake in J B Chemicals and Pharmaceuticals for Rs 19,500 crore, pending CCI approval. ...
- Torrent Pharma keen to break into big leagueTorrent Pharma, currently seventh in India, is aimingto break into the top three drugmakers within five years through strategic acquisition...
- Torrent Pharma board approves to raise Rs 5,000 croreTorrent Pharmaceuticals, actively seeking to expand through acquisitions, has expressed interest in purchasing Mumbai-based pharmaceutical ...
- Torrent Pharma says promoters haven't pledged sharesThe promoters are obligated to hold a minimum 26 per cent shares and management control of Torrent Pharma during the period of loans the co...
- Torrent Pharma completes acquisition of Unichem Laboratories Ltdhe acquisition will accelerate Torrent's presence in the chronic space especially in the high growth segments of Indian Pharma market like ...
- Buy Torrent Pharmaceuticals Ltd. target Rs 1730 : CLSACLSA upgraded Torrent Pharma to buy from outperform earlier with a 12-month target price to Rs 1730.
- Torrent Pharma buys Glochem Unit in VizagET had reported in its May 27 edition that the two companies are in advanced talks for a possible transaction.
- Torrent Pharma in advanced talks to buy Elder Pharma’s India businessTorrent Pharma is said to have offered Rs 1700 crores for buying the whole of India business of Elder Pharma.
- Torrent Pharma: Trading at a significant discount; a good betThe pharma major is trading at a significant discount to its peers and presents a good entry point.
Load More
